<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00665561</url>
  </required_header>
  <id_info>
    <org_study_id>A4001067</org_study_id>
    <secondary_id>2007-006148-24</secondary_id>
    <secondary_id>POEM</secondary_id>
    <nct_id>NCT00665561</nct_id>
  </id_info>
  <brief_title>Prospective Observational Epidemiologic Study of Maraviroc's Safety</brief_title>
  <acronym>POEM</acronym>
  <official_title>AN INTERNATIONAL, MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY OF THE SAFETY OF MARAVIROC USED WITH OPTIMIZED BACKGROUND THERAPY IN TREATMENT-EXPERIENCED HIV-1 INFECTED PATIENTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess if use of maraviroc along with an optimized background regimen of
      antiretroviral drugs in usual clinical practice is as safe as using only an optimized regimen
      of antiretroviral drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients meeting the study eligibility criteria at participating sites will be invited to
      participate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2008</start_date>
  <completion_date type="Actual">February 14, 2019</completion_date>
  <primary_completion_date type="Actual">February 14, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Density Rate Per 1000 Participant-Years for Incidence of Centers for Disease Control and Prevention Category C AIDS -Defining Opportunistic Infections</measure>
    <time_frame>Up to 5 years following enrollment</time_frame>
    <description>Density rate per 1000 participant-years for incidence of centers for disease control and prevention category C acquired immunodeficiency syndrome (AIDS) -defining opportunistic infections was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and confidence interval (CI).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Density Rate Per 1000 Participant-Years for Incidence of Viral Encephalitis</measure>
    <time_frame>Up to 5 years following enrollment</time_frame>
    <description>Density rate per 1000 participant-years for incidence of viral encephalitis was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Density Rate Per 1000 Participant-Years for Incidence of All Malignancies (AIDS Defining Malignancies and Non-AIDS Defining Malignancies)</measure>
    <time_frame>Up to 5 years following enrollment</time_frame>
    <description>Density rate per 1000 participant-years for incidence of all malignancies as well as its types (categorized as: AIDS defining malignancies and non-AIDS defining malignancies) were reported. AIDS defining malignancies included malignancies due to any of these: cervical cancer, Kaposi's sarcoma or lymphoma; whereas all other malignancies (except AIDS-defining) were non-aids defining malignancies. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Density Rate Per 1000 Participant-Years for Incidence of Liver Failure</measure>
    <time_frame>Up to 5 years following enrollment</time_frame>
    <description>Density rate per 1000 participant-years for incidence of liver failure was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Density Rate Per 1000 Participant-Years for Incidence of Myocardial Infarction or Ischemia: Events Adjudicated as 'Definite' or 'Possible'</measure>
    <time_frame>Up to 5 years following enrollment</time_frame>
    <description>Density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (definite + possible) was reported. Events of myocardial infarction or ischemia were adjudicated as definite or possible; where definite= an event had definitely occurred; possible =an event had possibly occurred. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI. In this outcome measure, density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (which included sum of definite + possible events) was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Density Rate Per 1000 Participant-Years for Incidence of Myocardial Infarction or Ischemia: Events Adjudicated as 'Definite' or 'Possible' or 'Insufficient Data'</measure>
    <time_frame>Up to 5 years following enrollment</time_frame>
    <description>Density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (definite + possible + insufficient data) was reported. Events of myocardial infarction or ischemia were adjudicated as definite or possible or insufficient data; where definite= an event had definitely occurred; possible =an event had possibly occurred; insufficient =insufficient data to determine whether an event had occurred. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI. In this outcome measure, density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (which included sum of definite + possible events + insufficient data) was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Density Rate Per 1000 Participant-Years for Incidence of Rhabdomyolysis</measure>
    <time_frame>Up to 5 years following enrollment</time_frame>
    <description>Density rate per 1000 participant-years for incidence of rhabdomyolysis was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Density Rate Per 1000 Participant-Years for Incidence of Death From Liver-Related Cause</measure>
    <time_frame>Up to 5 years following enrollment</time_frame>
    <description>Density rate per 1000 participant-years for incidence of death from liver-related cause was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Density Rate Per 1000 Participant-Years for Incidence of Death Due to Any Cause</measure>
    <time_frame>Up to 5 years following enrollment</time_frame>
    <description>Density rate per 1000 participant-years for incidence of death due to any cause was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjusted Density Rate Per 1000 Participant-Years for Incidence of Centers for Disease Control and Prevention Category C Aids-Defining Opportunistic Infections</measure>
    <time_frame>Up to 5 years following enrollment</time_frame>
    <description>Adjusted density rate per 1000 participant-years for incidence of centers for disease control and prevention category c aids-defining opportunistic infections was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with treatment as the main effect, propensity score (PS) quartile and imputed Framingham score (FS) as covariates in the model to obtain the adjusted rate and CI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjusted Density Rate Per 1000 Participant-Years for Incidence of All Malignancies (AIDS Defining Malignancies and Non-AIDS Defining Malignancies)</measure>
    <time_frame>Up to 5 years following enrollment</time_frame>
    <description>Adjusted density rate per 1000 participant-years for incidence of all malignancies as well as its types (categorized as AIDS defining malignancies and non-AIDS defining malignancies) were reported. AIDS defining malignancies included malignancies due to any of these: cervical cancer, Kaposi's sarcoma or lymphoma; whereas all other malignancies (except AIDS-defining) were non-AIDS defining malignancies. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with treatment as the main effect, PS quartile and imputed FS as covariates in the model to obtain the adjusted rate and CI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjusted Density Rate Per 1000 Participant-Years for Incidence of Myocardial Infarction or Ischemia: Events Adjudicated as 'Definite' or 'Possible'</measure>
    <time_frame>Up to 5 years following enrollment</time_frame>
    <description>Adjusted density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (definite + possible) was reported. Events of myocardial infarction or ischemia were adjudicated as definite or possible; where definite= an event had definitely occurred; possible =an event had possibly occurred. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with treatment as the main effect, PS quartile and imputed FS as covariates in the model to obtain the adjusted rate and CI. In this outcome measure, adjusted density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (which included sum of definite + possible events) was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjusted Density Rate Per 1000 Participant-Years for Incidence of Myocardial Infarction or Ischemia: Events Adjudicated as 'Definite' or 'Possible' or 'Insufficient Data'</measure>
    <time_frame>Up to 5 years following enrollment</time_frame>
    <description>Adjusted density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (definite + possible + insufficient data) was reported. Events of myocardial infarction or ischemia were adjudicated as definite or possible or insufficient data; where definite= an event had definitely occurred; possible =an event had possibly occurred; insufficient =insufficient data to determine whether an event had occurred. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with treatment as the main effect, PS quartile and imputed FS as covariates in the model to obtain the adjusted rate and CI. In this outcome measure, adjusted density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (which included sum of definite + possible events + insufficient data) was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjusted Density Rate Per 1000 Participant-Years for Incidence of Death Due to Any Cause</measure>
    <time_frame>Up to 5 years following enrollment</time_frame>
    <description>Adjusted density rate per 1000 participant-years for incidence of death due to any cause was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with treatment as the main effect, PS quartile and imputed FS as covariates in the model to obtain the adjusted rate and CI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With All-Cause Mortality</measure>
    <time_frame>Up to 5 years following enrollment</time_frame>
    <description>All-cause death was defined as the death due to any cause during the course of study.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">2455</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Maraviroc exposed</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Maraviroc unexposed</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc along with an optimized background antiretroviral drug regimen</intervention_name>
    <description>Maraviroc prescribed per approved local label.</description>
    <arm_group_label>Maraviroc exposed</arm_group_label>
    <other_name>Selzentry, Celsentri</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimized background antiretroviral drug regimen without maraviroc</intervention_name>
    <description>Optimized background antiretroviral therapy prescribed per approved local label and treatment guidelines.</description>
    <arm_group_label>Maraviroc unexposed</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Treatment experienced, HIV-1 infected patients in routine clinical practice.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment experienced, HIV-1 infected patients

          -  18 years or older

          -  Receive an approved assay for determination of HIV-1 tropism

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Using CCR5 inhibitor other than maraviroc
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Health Services Center</name>
      <address>
        <city>Hobson City</city>
        <state>Alabama</state>
        <zip>36201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AAC/Davis Clinic</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alabama Infectious Diseases Center</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Franco Antonio Felizarta MD</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Clinical Research</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lalla-Reddy Medical Corporation</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bickerstaff Pediatric Family HIV Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LA Gay and Lesbian Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Peter J. Ruane, MD</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alta Bates Summit Medical Center East Bay AIDS Center</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>95035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A Professional Corporation, Research Department</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford ACTG</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-5350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco Veterans Affairs Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Statnford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bipin Bhagat MD Inc.</name>
      <address>
        <city>Victorville</city>
        <state>California</state>
        <zip>92395</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanete of Colorado Rock Creek Medical Offices</name>
      <address>
        <city>Lafayette</city>
        <state>Colorado</state>
        <zip>80026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine Aids Program</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical AIDS &amp; HIV</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Saint Raphael</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Circle Medical, LLC</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06851</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dupont Circle Physician's Group</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Medical Counseling Service</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Infectious Diseases, George Washington University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University Medical Faculty Assoc</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Mahmoud H. Mustafa, MD, FACP</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ID Consultants Inc &amp; Infectious Disease Research Corp.</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel A. Warner/Consultive Medicine</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The McGregor Clinic</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Infectious Disease</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duval County Health Department</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Albert Canas, MD</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Resource</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Infectious Deisease and Tropical Medicine Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Positive</name>
      <address>
        <city>Safety Harbor</city>
        <state>Florida</state>
        <zip>34695</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinellas Care Clinic</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Research Institute, Inc</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midtown Medical Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital Comprehensive Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Care Clinic</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rowan Tree Medical, PA</name>
      <address>
        <city>Wilton Manors</city>
        <state>Florida</state>
        <zip>33305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Infectious Disease Group</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Health Care of Atlanta, PC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Absolute Care Medical Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30339-3915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Specialty Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Health Sciences University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WellStar Clinical Trials Office</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WellStar Infectious Disease</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WellStar Kennestone Hospital</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Associates</name>
      <address>
        <city>Riverdale</city>
        <state>Georgia</state>
        <zip>30274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chatham County Health Department</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruth M. Rothstein CORE Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Brown Health Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of William Johnson, M.D.</name>
      <address>
        <city>Olympia Fields</city>
        <state>Illinois</state>
        <zip>60461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southside Health Association</name>
      <address>
        <city>Olympia Fields</city>
        <state>Illinois</state>
        <zip>60461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blue Grass Care Clinic</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montgomery Infectious Disease Associates, P.A. (Private Practice)</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth's Medical Center</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research Institute</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Infectious Diseases Clinical Research</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Michigan Health Systems</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John hospital and Medical Center</name>
      <address>
        <city>Grosse Pointe Woods</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ingham County Health Department</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University College of Osteopathic Medicine</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newland Medical Associates</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal Medical Center Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Medical Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemechek Health Renewal</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111-2610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central West Clinical Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monmouth Medical Center</name>
      <address>
        <city>Long Branch</city>
        <state>New Jersey</state>
        <zip>07740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jersey Shore Medical Center</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Medical Associates</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Michael's Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erie County Medical Center, HIV Services</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guthrie Medical Group</name>
      <address>
        <city>Ithaca</city>
        <state>New York</state>
        <zip>14850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Clinic</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIV &amp; Internal Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Downtown Comprehensive Health Program</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CUMC Research Pharmacy</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Care</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westchester Medical Center</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ID Associates</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosedale Infectious Diseases</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toledo: Health Sciences Campus</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research and Education Group</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Northwest Region, Immune Deficiency Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health Medical Services</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-6073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia Fight</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guthrie Clinic, Ltd.</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Low Country Infectious Diseases, P.A.</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCC Clinic</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Carolina School of Medicine</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Speciality Clinics</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Hope Foundation</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas VA Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Infectious Disease Clinical Research, Inc.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center HIV/AIDS Research Unit</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pillar Clinical Research LLC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Allan Rowan Kelly MD</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tarrant County Infectious Disease Assocciates</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tarrant County Infectious Disease Associates</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Garcias' Family Health Group</name>
      <address>
        <city>Harlingen</city>
        <state>Texas</state>
        <zip>78550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Aids Council</name>
      <address>
        <city>Harlingen</city>
        <state>Texas</state>
        <zip>78550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael E. DeBakey Veterans Affairs Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diversified Medical Practices, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Howard Kussman, MD</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Care System</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Veterans Health Care System</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Associates of Central Virginia</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <zip>24541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Associates of Central Virginia</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Group Health Cooperative</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshall University Joan C. Edwards School of Medicine</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Tropical Medicine</name>
      <address>
        <city>Antwerpen</city>
        <zip>B-2000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint Pierre</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gasthuisberg, Inwendige Geneeskunde</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. Sart-Tilman</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dia</name>
      <address>
        <city>Brasilia</city>
        <state>DF</state>
        <zip>70351-580</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto A.Z. de Pesquisa e Ensino</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80240-280</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Geral de Nova Iguacu</name>
      <address>
        <city>Nova Iguacu</city>
        <state>RJ</state>
        <zip>26030-380</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo Andr</city>
        <state>SP</state>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Referencia e Treinamento DST/AIDS</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04121-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Heliopolis</name>
      <address>
        <city>So Paulo</city>
        <state>SP</state>
        <zip>04231-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia/ Downtown Infectious Diseases Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Medicale du Quartier Latin</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 5B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM, Hotel-Dieu Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Recherche Clinique Mdicale des Campus</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Jean Verdier, Unite de maladies infectieuses</name>
      <address>
        <city>Bondy</city>
        <zip>93140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-andre CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raymond Poincare Hospital</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de L'Hotel Dieu</name>
      <address>
        <city>Lyon</city>
        <zip>69288</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte Marguerite</name>
      <address>
        <city>Marseille Cedex 09</city>
        <zip>13274</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cochin Hospital Saint Vincent de Paul</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Louis Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Perpignan</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hpital Haut - Leveque - Centre Francois Magendie</name>
      <address>
        <city>PESSAC Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033 Cedex 09</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Tourcoing</name>
      <address>
        <city>Tourcoing</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arztpraxis fuer Innere Medizin Dr. Knechten</name>
      <address>
        <city>Aachen</city>
        <zip>52062</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis City Ost Medizinisches Zentrum</name>
      <address>
        <city>Berlin</city>
        <zip>10243</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Christiane Cordes</name>
      <address>
        <city>Berlin</city>
        <zip>D-10243</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus, Klinik und Poliklinik fuer Dermatologie</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the J.W. Goethe University, Medical Clinic II</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Lothar Schneider Interne Medizin, HIV Schwerpunkt</name>
      <address>
        <city>Fuerth</city>
        <zip>90762</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPM - Study - Center</name>
      <address>
        <city>Hamburg</city>
        <zip>20146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ifi-Institut am Allgemeines Krankenhaus St.Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg-Eppendorf, Ambulanzzentrum des UKE GmbH, Bereich Infektiologie</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik I fuer Innere Medizin der Uni-Klinik Koeln</name>
      <address>
        <city>Koeln</city>
        <zip>D-50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Mainz, I. Medizinische Klinik und Poliklinik,</name>
      <address>
        <city>Mainz</city>
        <zip>D-55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mannheimer Onkologie Praxis</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Untersendling</name>
      <address>
        <city>Muenchen</city>
        <zip>81371</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum</name>
      <address>
        <city>Muenchen</city>
        <zip>D 80335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-Universitaet, Klinikum Innenstadt, Medizinische Poliklinik</name>
      <address>
        <city>Muenchen</city>
        <zip>D-80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum fuer interdisziplinaere Medizin Muenster GmbH</name>
      <address>
        <city>Muenster</city>
        <zip>48143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Osnabruck</name>
      <address>
        <city>Osnabruck</city>
        <zip>D-49090</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectomed GbR Zentrum fr medizinische Studien</name>
      <address>
        <city>Stuttgart</city>
        <zip>D-70197</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Privatpraxis Ulmer, Frietsch, Mller</name>
      <address>
        <city>Stuttgart</city>
        <zip>D-70197</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Patras</name>
      <address>
        <city>Patras</city>
        <state>Achaia</state>
        <zip>26 500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andreas Syngros Hospital</name>
      <address>
        <city>Athens</city>
        <zip>161 21</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tzaneion General Hospital of Piraeus</name>
      <address>
        <city>Piraues</city>
        <zip>185 36</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Malattie Infettive</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ambulatorio Day Hospital Malattie Infettive</name>
      <address>
        <city>Bologna</city>
        <zip>40133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Clinica Specialistica e Sperimentale</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Busto Arsizio Hospital</name>
      <address>
        <city>Busto Arsizio-Varese</city>
        <zip>21052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOD Malattie Infettive, La Piastra dei Servizi</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ente Ospedaliero Ospedali Galliera</name>
      <address>
        <city>Genova</city>
        <zip>16128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1 Divisione di Malattive Infettive e Servizio di Allergologia, Ospedale L. Sacco</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita' degli Studi di Milano, Dipartimento di scienza clinica Luigi Sacco</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Raffaele Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Infectious and Tropical Diseases-University of Milan-San Paolo Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedal Universitaria II Univ degli Studi di Napoli Servizio di Diagnosi e Terapia</name>
      <address>
        <city>Naples</city>
        <zip>80135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;Domenico Cotugno&quot;</name>
      <address>
        <city>Napoli</city>
        <zip>80137</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOUP Paolo Giaccone, UOC Malattie Infettive</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Locale Ospedale Civile dello Spirito Santo Presidio Ospedaliero</name>
      <address>
        <city>Pescara</city>
        <zip>65100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Malattie Infettive &quot;L.Spallanzani&quot;-IRCCS</name>
      <address>
        <city>Roma</city>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Malattie Infettive INMI- &quot;L. Spallanzani&quot;- I.R.C.C.S.</name>
      <address>
        <city>Roma</city>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita' di Roma La Sapienza, Dipartimento di Malattie Infettive e Tropicali</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita'Cattolica del Sacro Cuore Policlinico Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Giovanni Addolorata Presidia Santa Maria</name>
      <address>
        <city>Rome</city>
        <zip>00184</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Amedeo di Savoia</name>
      <address>
        <city>Torino</city>
        <zip>10100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Amedeo di Savoia, Clinica Universitaria di Malattie Infettive</name>
      <address>
        <city>Torino</city>
        <zip>10149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ararat Research Center</name>
      <address>
        <city>Ponce</city>
        <zip>00717-1567</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPE Clinical Research</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro</name>
      <address>
        <city>Logroo</city>
        <state>LA Rioja</state>
        <zip>26006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Tortosa Verge de La Cinta</name>
      <address>
        <city>Tortosa</city>
        <state>Tarragona</state>
        <zip>43500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Juan Canalejo</name>
      <address>
        <city>A Corua</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitrio de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Tias I Pujol</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Enfermedades Infecciosas</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Cecilio</name>
      <address>
        <city>Granada</city>
        <zip>18012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Iii</name>
      <address>
        <city>Madrid</city>
        <zip>28029</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mataro Hospital</name>
      <address>
        <city>Mataro</city>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Mostoles</name>
      <address>
        <city>Mostoles, Madrid</city>
        <zip>28935</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Donostia</name>
      <address>
        <city>San Sebastian</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de La Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Tenerife</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hull &amp; East Yorkshire Hospitals NHS Trust</name>
      <address>
        <city>Cottingham</city>
        <state>EAST Yorkshire</state>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Resource Building, Level 7</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <state>Newcastle</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Selly Oak Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brighton and Sussex University Hospitals NHS Trust</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 1ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Manchester General Hospital</name>
      <address>
        <city>Crumpsall, Manchester</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Darlington Memorial Hospital</name>
      <address>
        <city>Darlington</city>
        <zip>DL36HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Infectious Diseases Unit</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grahame Hayton Unit</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Middlesex Hospital</name>
      <address>
        <city>London</city>
        <zip>N18 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital, Ian Charleson Day Centre</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Floor St Stephens Centre</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren browne Unit, Southlands Hospital</name>
      <address>
        <city>Shoreham-by-sea, West Sussex</city>
        <zip>BN43 6TQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cobridge Community Health Centre</name>
      <address>
        <city>Stoke On Trent, Staffordshire</city>
        <zip>ST6 2JW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George's Hospital</name>
      <address>
        <city>Tooting</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Portugal</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4001067&amp;StudyName=Prospective%20Observational%20Epidemiologic%20Study%20of%20Maraviroc%27s%20Safety</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 23, 2008</study_first_submitted>
  <study_first_submitted_qc>April 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2008</study_first_posted>
  <results_first_submitted>February 12, 2020</results_first_submitted>
  <results_first_submitted_qc>March 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 7, 2020</results_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Maraviroc</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Safety</keyword>
  <keyword>Non-interventional</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
    <mesh_term>Anti-Retroviral Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 29, 2010</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT00665561/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 21, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT00665561/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Study was conducted at multiple sites between 31 March 2008 and 14 February 2019.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Maraviroc Exposed</title>
          <description>Human immunodeficiency virus- 1( HIV-1) infected, treatment-experienced adult participants, who were prescribed with maraviroc along with an optimized background antiretroviral therapy (OBT) regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
        </group>
        <group group_id="P2">
          <title>Maraviroc Unexposed</title>
          <description>HIV-1 infected, treatment-experienced adult participants, who were not prescribed with maraviroc but with OBT regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1316"/>
                <participants group_id="P2" count="1130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="814"/>
                <participants group_id="P2" count="596"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="502"/>
                <participants group_id="P2" count="534"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death recorded on subject summary pages</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Does not meet entrance criteria</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
                <participants group_id="P2" count="264"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="108"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site closed</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn due to pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set: All participants who were enrolled in the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Maraviroc Exposed</title>
          <description>Human immunodeficiency virus- 1( HIV-1) infected, treatment-experienced adult participants, who were prescribed with maraviroc along with an optimized background antiretroviral therapy (OBT) regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
        </group>
        <group group_id="B2">
          <title>Maraviroc Unexposed</title>
          <description>HIV-1 infected, treatment-experienced adult participants, who were not prescribed with maraviroc but with OBT regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1316"/>
            <count group_id="B2" value="1130"/>
            <count group_id="B3" value="2446"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.8" spread="9.3"/>
                    <measurement group_id="B2" value="44.3" spread="10.0"/>
                    <measurement group_id="B3" value="45.6" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="275"/>
                    <measurement group_id="B2" value="265"/>
                    <measurement group_id="B3" value="540"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1041"/>
                    <measurement group_id="B2" value="865"/>
                    <measurement group_id="B3" value="1906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="983"/>
                    <measurement group_id="B2" value="684"/>
                    <measurement group_id="B3" value="1667"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="271"/>
                    <measurement group_id="B2" value="390"/>
                    <measurement group_id="B3" value="661"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unspecified</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Density Rate Per 1000 Participant-Years for Incidence of Centers for Disease Control and Prevention Category C AIDS -Defining Opportunistic Infections</title>
        <description>Density rate per 1000 participant-years for incidence of centers for disease control and prevention category C acquired immunodeficiency syndrome (AIDS) -defining opportunistic infections was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and confidence interval (CI).</description>
        <time_frame>Up to 5 years following enrollment</time_frame>
        <population>Safety analysis set included all participants who were enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc Exposed</title>
            <description>Human immunodeficiency virus- 1( HIV-1) infected, treatment-experienced adult participants, who were prescribed with maraviroc along with an optimized background antiretroviral therapy (OBT) regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc Unexposed</title>
            <description>HIV-1 infected, treatment-experienced adult participants, who were not prescribed with maraviroc but with OBT regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Density Rate Per 1000 Participant-Years for Incidence of Centers for Disease Control and Prevention Category C AIDS -Defining Opportunistic Infections</title>
          <description>Density rate per 1000 participant-years for incidence of centers for disease control and prevention category C acquired immunodeficiency syndrome (AIDS) -defining opportunistic infections was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and confidence interval (CI).</description>
          <population>Safety analysis set included all participants who were enrolled in the study.</population>
          <units>events per 1000 participant-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1316"/>
                <count group_id="O2" value="1130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.28" lower_limit="18.57" upper_limit="26.73"/>
                    <measurement group_id="O2" value="41.77" lower_limit="36.09" upper_limit="48.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude risk ratio (RR) and CI.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Density Rate Per 1000 Participant-Years for Incidence of Viral Encephalitis</title>
        <description>Density rate per 1000 participant-years for incidence of viral encephalitis was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI.</description>
        <time_frame>Up to 5 years following enrollment</time_frame>
        <population>Safety analysis set included all participants who were enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc Exposed</title>
            <description>Human immunodeficiency virus- 1( HIV-1) infected, treatment-experienced adult participants, who were prescribed with maraviroc along with an optimized background antiretroviral therapy (OBT) regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc Unexposed</title>
            <description>HIV-1 infected, treatment-experienced adult participants, who were not prescribed with maraviroc but with OBT regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Density Rate Per 1000 Participant-Years for Incidence of Viral Encephalitis</title>
          <description>Density rate per 1000 participant-years for incidence of viral encephalitis was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI.</description>
          <population>Safety analysis set included all participants who were enrolled in the study.</population>
          <units>events per 1000 participant-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1316"/>
                <count group_id="O2" value="1130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" lower_limit="0.10" upper_limit="1.54"/>
                    <measurement group_id="O2" value="0.46" lower_limit="0.12" upper_limit="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude RR and CI.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>5.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Density Rate Per 1000 Participant-Years for Incidence of All Malignancies (AIDS Defining Malignancies and Non-AIDS Defining Malignancies)</title>
        <description>Density rate per 1000 participant-years for incidence of all malignancies as well as its types (categorized as: AIDS defining malignancies and non-AIDS defining malignancies) were reported. AIDS defining malignancies included malignancies due to any of these: cervical cancer, Kaposi's sarcoma or lymphoma; whereas all other malignancies (except AIDS-defining) were non-aids defining malignancies. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI.</description>
        <time_frame>Up to 5 years following enrollment</time_frame>
        <population>Safety analysis set included all participants who were enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc Exposed</title>
            <description>Human immunodeficiency virus- 1( HIV-1) infected, treatment-experienced adult participants, who were prescribed with maraviroc along with an optimized background antiretroviral therapy (OBT) regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc Unexposed</title>
            <description>HIV-1 infected, treatment-experienced adult participants, who were not prescribed with maraviroc but with OBT regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Density Rate Per 1000 Participant-Years for Incidence of All Malignancies (AIDS Defining Malignancies and Non-AIDS Defining Malignancies)</title>
          <description>Density rate per 1000 participant-years for incidence of all malignancies as well as its types (categorized as: AIDS defining malignancies and non-AIDS defining malignancies) were reported. AIDS defining malignancies included malignancies due to any of these: cervical cancer, Kaposi's sarcoma or lymphoma; whereas all other malignancies (except AIDS-defining) were non-aids defining malignancies. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI.</description>
          <population>Safety analysis set included all participants who were enrolled in the study.</population>
          <units>events per 1000 participant-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1316"/>
                <count group_id="O2" value="1130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Malignancies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.87" lower_limit="10.13" upper_limit="16.35"/>
                    <measurement group_id="O2" value="13.69" lower_limit="10.61" upper_limit="17.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AIDS defining Malignancies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" lower_limit="1.31" upper_limit="4.06"/>
                    <measurement group_id="O2" value="3.71" lower_limit="2.27" upper_limit="6.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-AIDS defining Malignancies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.56" lower_limit="8.11" upper_limit="13.76"/>
                    <measurement group_id="O2" value="9.98" lower_limit="7.40" upper_limit="13.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All Malignancies: Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude RR and CI.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AIDS defining Malignancies: Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude RR and CI.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-AIDS defining Malignancies: Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude RR and CI.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Density Rate Per 1000 Participant-Years for Incidence of Liver Failure</title>
        <description>Density rate per 1000 participant-years for incidence of liver failure was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI.</description>
        <time_frame>Up to 5 years following enrollment</time_frame>
        <population>Safety analysis set included all participants who were enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc Exposed</title>
            <description>Human immunodeficiency virus- 1( HIV-1) infected, treatment-experienced adult participants, who were prescribed with maraviroc along with an optimized background antiretroviral therapy (OBT) regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc Unexposed</title>
            <description>HIV-1 infected, treatment-experienced adult participants, who were not prescribed with maraviroc but with OBT regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Density Rate Per 1000 Participant-Years for Incidence of Liver Failure</title>
          <description>Density rate per 1000 participant-years for incidence of liver failure was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI.</description>
          <population>Safety analysis set included all participants who were enrolled in the study.</population>
          <units>events per 1000 participant-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1316"/>
                <count group_id="O2" value="1130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" lower_limit="1.45" upper_limit="4.30"/>
                    <measurement group_id="O2" value="2.55" lower_limit="1.41" upper_limit="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude RR and CI.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>2.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Density Rate Per 1000 Participant-Years for Incidence of Myocardial Infarction or Ischemia: Events Adjudicated as 'Definite' or 'Possible'</title>
        <description>Density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (definite + possible) was reported. Events of myocardial infarction or ischemia were adjudicated as definite or possible; where definite= an event had definitely occurred; possible =an event had possibly occurred. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI. In this outcome measure, density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (which included sum of definite + possible events) was reported.</description>
        <time_frame>Up to 5 years following enrollment</time_frame>
        <population>Safety analysis set included all participants who were enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc Exposed</title>
            <description>Human immunodeficiency virus- 1( HIV-1) infected, treatment-experienced adult participants, who were prescribed with maraviroc along with an optimized background antiretroviral therapy (OBT) regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc Unexposed</title>
            <description>HIV-1 infected, treatment-experienced adult participants, who were not prescribed with maraviroc but with OBT regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Density Rate Per 1000 Participant-Years for Incidence of Myocardial Infarction or Ischemia: Events Adjudicated as 'Definite' or 'Possible'</title>
          <description>Density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (definite + possible) was reported. Events of myocardial infarction or ischemia were adjudicated as definite or possible; where definite= an event had definitely occurred; possible =an event had possibly occurred. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI. In this outcome measure, density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (which included sum of definite + possible events) was reported.</description>
          <population>Safety analysis set included all participants who were enrolled in the study.</population>
          <units>events per 1000 participant-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1316"/>
                <count group_id="O2" value="1130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80" lower_limit="3.24" upper_limit="7.11"/>
                    <measurement group_id="O2" value="5.34" lower_limit="3.55" upper_limit="8.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude RR and CI.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Density Rate Per 1000 Participant-Years for Incidence of Myocardial Infarction or Ischemia: Events Adjudicated as 'Definite' or 'Possible' or 'Insufficient Data'</title>
        <description>Density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (definite + possible + insufficient data) was reported. Events of myocardial infarction or ischemia were adjudicated as definite or possible or insufficient data; where definite= an event had definitely occurred; possible =an event had possibly occurred; insufficient =insufficient data to determine whether an event had occurred. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI. In this outcome measure, density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (which included sum of definite + possible events + insufficient data) was reported.</description>
        <time_frame>Up to 5 years following enrollment</time_frame>
        <population>Safety analysis set included all participants who were enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc Exposed</title>
            <description>Human immunodeficiency virus- 1( HIV-1) infected, treatment-experienced adult participants, who were prescribed with maraviroc along with an optimized background antiretroviral therapy (OBT) regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc Unexposed</title>
            <description>HIV-1 infected, treatment-experienced adult participants, who were not prescribed with maraviroc but with OBT regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Density Rate Per 1000 Participant-Years for Incidence of Myocardial Infarction or Ischemia: Events Adjudicated as 'Definite' or 'Possible' or 'Insufficient Data'</title>
          <description>Density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (definite + possible + insufficient data) was reported. Events of myocardial infarction or ischemia were adjudicated as definite or possible or insufficient data; where definite= an event had definitely occurred; possible =an event had possibly occurred; insufficient =insufficient data to determine whether an event had occurred. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI. In this outcome measure, density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (which included sum of definite + possible events + insufficient data) was reported.</description>
          <population>Safety analysis set included all participants who were enrolled in the study.</population>
          <units>events per 1000 participant-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1316"/>
                <count group_id="O2" value="1130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.26" lower_limit="6.13" upper_limit="11.14"/>
                    <measurement group_id="O2" value="7.43" lower_limit="5.25" upper_limit="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude RR and CI.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Density Rate Per 1000 Participant-Years for Incidence of Rhabdomyolysis</title>
        <description>Density rate per 1000 participant-years for incidence of rhabdomyolysis was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI.</description>
        <time_frame>Up to 5 years following enrollment</time_frame>
        <population>Safety analysis set included all participants who were enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc Exposed</title>
            <description>Human immunodeficiency virus- 1( HIV-1) infected, treatment-experienced adult participants, who were prescribed with maraviroc along with an optimized background antiretroviral therapy (OBT) regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc Unexposed</title>
            <description>HIV-1 infected, treatment-experienced adult participants, who were not prescribed with maraviroc but with OBT regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Density Rate Per 1000 Participant-Years for Incidence of Rhabdomyolysis</title>
          <description>Density rate per 1000 participant-years for incidence of rhabdomyolysis was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI.</description>
          <population>Safety analysis set included all participants who were enrolled in the study.</population>
          <units>events per 1000 participant-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1316"/>
                <count group_id="O2" value="1130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" lower_limit="0.29" upper_limit="2.05"/>
                    <measurement group_id="O2" value="0.70" lower_limit="0.22" upper_limit="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude RR and CI.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>4.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Density Rate Per 1000 Participant-Years for Incidence of Death From Liver-Related Cause</title>
        <description>Density rate per 1000 participant-years for incidence of death from liver-related cause was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI.</description>
        <time_frame>Up to 5 years following enrollment</time_frame>
        <population>Safety analysis set included all participants who were enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc Exposed</title>
            <description>Human immunodeficiency virus- 1( HIV-1) infected, treatment-experienced adult participants, who were prescribed with maraviroc along with an optimized background antiretroviral therapy (OBT) regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc Unexposed</title>
            <description>HIV-1 infected, treatment-experienced adult participants, who were not prescribed with maraviroc but with OBT regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Density Rate Per 1000 Participant-Years for Incidence of Death From Liver-Related Cause</title>
          <description>Density rate per 1000 participant-years for incidence of death from liver-related cause was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI.</description>
          <population>Safety analysis set included all participants who were enrolled in the study.</population>
          <units>events per 1000 participant-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1316"/>
                <count group_id="O2" value="1130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" lower_limit="0.29" upper_limit="2.05"/>
                    <measurement group_id="O2" value="1.16" lower_limit="0.48" upper_limit="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude RR and CI.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>2.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Density Rate Per 1000 Participant-Years for Incidence of Death Due to Any Cause</title>
        <description>Density rate per 1000 participant-years for incidence of death due to any cause was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI.</description>
        <time_frame>Up to 5 years following enrollment</time_frame>
        <population>Safety analysis set included all participants who were enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc Exposed</title>
            <description>Human immunodeficiency virus- 1( HIV-1) infected, treatment-experienced adult participants, who were prescribed with maraviroc along with an optimized background antiretroviral therapy (OBT) regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc Unexposed</title>
            <description>HIV-1 infected, treatment-experienced adult participants, who were not prescribed with maraviroc but with OBT regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Density Rate Per 1000 Participant-Years for Incidence of Death Due to Any Cause</title>
          <description>Density rate per 1000 participant-years for incidence of death due to any cause was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude rate and CI.</description>
          <population>Safety analysis set included all participants who were enrolled in the study.</population>
          <units>events per 1000 participant-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1316"/>
                <count group_id="O2" value="1130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.41" lower_limit="11.49" upper_limit="18.07"/>
                    <measurement group_id="O2" value="18.33" lower_limit="14.70" upper_limit="22.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poisson regressions were fit to the categorical events with only treatment in the model to obtain the crude RR and CI.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Density Rate Per 1000 Participant-Years for Incidence of Centers for Disease Control and Prevention Category C Aids-Defining Opportunistic Infections</title>
        <description>Adjusted density rate per 1000 participant-years for incidence of centers for disease control and prevention category c aids-defining opportunistic infections was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with treatment as the main effect, propensity score (PS) quartile and imputed Framingham score (FS) as covariates in the model to obtain the adjusted rate and CI.</description>
        <time_frame>Up to 5 years following enrollment</time_frame>
        <population>Safety analysis set included all participants who were enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc Exposed</title>
            <description>Human immunodeficiency virus- 1( HIV-1) infected, treatment-experienced adult participants, who were prescribed with maraviroc along with an optimized background antiretroviral therapy (OBT) regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc Unexposed</title>
            <description>HIV-1 infected, treatment-experienced adult participants, who were not prescribed with maraviroc but with OBT regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Density Rate Per 1000 Participant-Years for Incidence of Centers for Disease Control and Prevention Category C Aids-Defining Opportunistic Infections</title>
          <description>Adjusted density rate per 1000 participant-years for incidence of centers for disease control and prevention category c aids-defining opportunistic infections was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with treatment as the main effect, propensity score (PS) quartile and imputed Framingham score (FS) as covariates in the model to obtain the adjusted rate and CI.</description>
          <population>Safety analysis set included all participants who were enrolled in the study.</population>
          <units>events per 1000 participant-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1316"/>
                <count group_id="O2" value="1130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.36" lower_limit="18.56" upper_limit="26.94"/>
                    <measurement group_id="O2" value="28.70" lower_limit="23.98" upper_limit="34.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poisson regressions were fit to the categorical events with treatment as the main effect, PS quartile and imputed FS as covariates in the model to obtain the adjusted RR and CI.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Density Rate Per 1000 Participant-Years for Incidence of All Malignancies (AIDS Defining Malignancies and Non-AIDS Defining Malignancies)</title>
        <description>Adjusted density rate per 1000 participant-years for incidence of all malignancies as well as its types (categorized as AIDS defining malignancies and non-AIDS defining malignancies) were reported. AIDS defining malignancies included malignancies due to any of these: cervical cancer, Kaposi's sarcoma or lymphoma; whereas all other malignancies (except AIDS-defining) were non-AIDS defining malignancies. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with treatment as the main effect, PS quartile and imputed FS as covariates in the model to obtain the adjusted rate and CI.</description>
        <time_frame>Up to 5 years following enrollment</time_frame>
        <population>Safety analysis set included all participants who were enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc Exposed</title>
            <description>Human immunodeficiency virus- 1( HIV-1) infected, treatment-experienced adult participants, who were prescribed with maraviroc along with an optimized background antiretroviral therapy (OBT) regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc Unexposed</title>
            <description>HIV-1 infected, treatment-experienced adult participants, who were not prescribed with maraviroc but with OBT regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Density Rate Per 1000 Participant-Years for Incidence of All Malignancies (AIDS Defining Malignancies and Non-AIDS Defining Malignancies)</title>
          <description>Adjusted density rate per 1000 participant-years for incidence of all malignancies as well as its types (categorized as AIDS defining malignancies and non-AIDS defining malignancies) were reported. AIDS defining malignancies included malignancies due to any of these: cervical cancer, Kaposi's sarcoma or lymphoma; whereas all other malignancies (except AIDS-defining) were non-AIDS defining malignancies. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with treatment as the main effect, PS quartile and imputed FS as covariates in the model to obtain the adjusted rate and CI.</description>
          <population>Safety analysis set included all participants who were enrolled in the study.</population>
          <units>events per 1000 participant-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1316"/>
                <count group_id="O2" value="1130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Malignancies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.49" lower_limit="9.72" upper_limit="16.05"/>
                    <measurement group_id="O2" value="13.54" lower_limit="10.44" upper_limit="17.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AIDS defining Malignancies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" lower_limit="1.29" upper_limit="4.13"/>
                    <measurement group_id="O2" value="3.31" lower_limit="1.95" upper_limit="5.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-AIDS defining Malignancies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.87" lower_limit="7.44" upper_limit="13.09"/>
                    <measurement group_id="O2" value="9.86" lower_limit="7.27" upper_limit="13.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All malignancies: Poisson regressions were fit to the categorical events with treatment as the main effect, PS quartile and imputed FS as covariates in the model to obtain the adjusted RR and CI.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AIDS defining malignancies: Poisson regressions were fit to the categorical events with treatment as the main effect, PS quartile and imputed FS as covariates in the model to obtain the adjusted RR and CI.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-AIDS defining malignancies: Poisson regressions were fit to the categorical events with treatment as the main effect, PS quartile and imputed FS as covariates in the model to obtain the adjusted RR and CI.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Density Rate Per 1000 Participant-Years for Incidence of Myocardial Infarction or Ischemia: Events Adjudicated as 'Definite' or 'Possible'</title>
        <description>Adjusted density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (definite + possible) was reported. Events of myocardial infarction or ischemia were adjudicated as definite or possible; where definite= an event had definitely occurred; possible =an event had possibly occurred. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with treatment as the main effect, PS quartile and imputed FS as covariates in the model to obtain the adjusted rate and CI. In this outcome measure, adjusted density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (which included sum of definite + possible events) was reported.</description>
        <time_frame>Up to 5 years following enrollment</time_frame>
        <population>Safety analysis set included all participants who were enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc Exposed</title>
            <description>Human immunodeficiency virus- 1( HIV-1) infected, treatment-experienced adult participants, who were prescribed with maraviroc along with an optimized background antiretroviral therapy (OBT) regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc Unexposed</title>
            <description>HIV-1 infected, treatment-experienced adult participants, who were not prescribed with maraviroc but with OBT regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Density Rate Per 1000 Participant-Years for Incidence of Myocardial Infarction or Ischemia: Events Adjudicated as 'Definite' or 'Possible'</title>
          <description>Adjusted density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (definite + possible) was reported. Events of myocardial infarction or ischemia were adjudicated as definite or possible; where definite= an event had definitely occurred; possible =an event had possibly occurred. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with treatment as the main effect, PS quartile and imputed FS as covariates in the model to obtain the adjusted rate and CI. In this outcome measure, adjusted density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (which included sum of definite + possible events) was reported.</description>
          <population>Safety analysis set included all participants who were enrolled in the study.</population>
          <units>events per 1000 participant-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1316"/>
                <count group_id="O2" value="1130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" lower_limit="1.21" upper_limit="3.56"/>
                    <measurement group_id="O2" value="3.37" lower_limit="2.06" upper_limit="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poisson regressions were fit to the categorical events with treatment as the main effect, PS quartile and imputed FS as covariates in the model to obtain the adjusted RR and CI.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Density Rate Per 1000 Participant-Years for Incidence of Myocardial Infarction or Ischemia: Events Adjudicated as 'Definite' or 'Possible' or 'Insufficient Data'</title>
        <description>Adjusted density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (definite + possible + insufficient data) was reported. Events of myocardial infarction or ischemia were adjudicated as definite or possible or insufficient data; where definite= an event had definitely occurred; possible =an event had possibly occurred; insufficient =insufficient data to determine whether an event had occurred. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with treatment as the main effect, PS quartile and imputed FS as covariates in the model to obtain the adjusted rate and CI. In this outcome measure, adjusted density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (which included sum of definite + possible events + insufficient data) was reported.</description>
        <time_frame>Up to 5 years following enrollment</time_frame>
        <population>Safety analysis set included all participants who were enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc Exposed</title>
            <description>Human immunodeficiency virus- 1( HIV-1) infected, treatment-experienced adult participants, who were prescribed with maraviroc along with an optimized background antiretroviral therapy (OBT) regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc Unexposed</title>
            <description>HIV-1 infected, treatment-experienced adult participants, who were not prescribed with maraviroc but with OBT regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Density Rate Per 1000 Participant-Years for Incidence of Myocardial Infarction or Ischemia: Events Adjudicated as 'Definite' or 'Possible' or 'Insufficient Data'</title>
          <description>Adjusted density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (definite + possible + insufficient data) was reported. Events of myocardial infarction or ischemia were adjudicated as definite or possible or insufficient data; where definite= an event had definitely occurred; possible =an event had possibly occurred; insufficient =insufficient data to determine whether an event had occurred. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with treatment as the main effect, PS quartile and imputed FS as covariates in the model to obtain the adjusted rate and CI. In this outcome measure, adjusted density rate per 1000 participant-years for incidence of myocardial infarction or ischemia (which included sum of definite + possible events + insufficient data) was reported.</description>
          <population>Safety analysis set included all participants who were enrolled in the study.</population>
          <units>events per 1000 participant-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1316"/>
                <count group_id="O2" value="1130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.65" lower_limit="3.97" upper_limit="8.05"/>
                    <measurement group_id="O2" value="5.99" lower_limit="4.13" upper_limit="8.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poisson regressions were fit to the categorical events with treatment as the main effect, PS quartile and imputed FS as covariates in the model to obtain the adjusted RR and CI.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Density Rate Per 1000 Participant-Years for Incidence of Death Due to Any Cause</title>
        <description>Adjusted density rate per 1000 participant-years for incidence of death due to any cause was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with treatment as the main effect, PS quartile and imputed FS as covariates in the model to obtain the adjusted rate and CI.</description>
        <time_frame>Up to 5 years following enrollment</time_frame>
        <population>Safety analysis set included all participants who were enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc Exposed</title>
            <description>Human immunodeficiency virus- 1( HIV-1) infected, treatment-experienced adult participants, who were prescribed with maraviroc along with an optimized background antiretroviral therapy (OBT) regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc Unexposed</title>
            <description>HIV-1 infected, treatment-experienced adult participants, who were not prescribed with maraviroc but with OBT regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Density Rate Per 1000 Participant-Years for Incidence of Death Due to Any Cause</title>
          <description>Adjusted density rate per 1000 participant-years for incidence of death due to any cause was reported. Density rate was calculated as the number of events (n) per 1000 participant-years at risk. Poisson regressions were fit to the categorical events with treatment as the main effect, PS quartile and imputed FS as covariates in the model to obtain the adjusted rate and CI.</description>
          <population>Safety analysis set included all participants who were enrolled in the study.</population>
          <units>events per 1000 participant-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1316"/>
                <count group_id="O2" value="1130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.39" lower_limit="11.41" upper_limit="18.16"/>
                    <measurement group_id="O2" value="15.64" lower_limit="12.30" upper_limit="19.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poisson regressions were fit to the categorical events with treatment as the main effect, PS quartile and imputed FS as covariates in the model to obtain the adjusted RR and CI.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With All-Cause Mortality</title>
        <description>All-cause death was defined as the death due to any cause during the course of study.</description>
        <time_frame>Up to 5 years following enrollment</time_frame>
        <population>Safety analysis set included all participants who were enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc Exposed</title>
            <description>Human immunodeficiency virus- 1( HIV-1) infected, treatment-experienced adult participants, who were prescribed with maraviroc along with an optimized background antiretroviral therapy (OBT) regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc Unexposed</title>
            <description>HIV-1 infected, treatment-experienced adult participants, who were not prescribed with maraviroc but with OBT regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With All-Cause Mortality</title>
          <description>All-cause death was defined as the death due to any cause during the course of study.</description>
          <population>Safety analysis set included all participants who were enrolled in the study.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1316"/>
                <count group_id="O2" value="1130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                    <measurement group_id="O2" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6225</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 5 years following enrollment</time_frame>
      <desc>Same event may appear as adverse event (AE) and serious AE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as non-serious in another or 1 participant may have experienced both serious and non-serious event during study. Four participants in the arm MVC-unexposed group were not counted under death reason of discontinuation, because these deaths were not recorded on participant summary page at the time of reason of discontinuation analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Maraviroc Exposed</title>
          <description>Human immunodeficiency virus- 1( HIV-1) infected, treatment-experienced adult participants, who were prescribed with maraviroc along with an optimized background antiretroviral therapy (OBT) regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
        </group>
        <group group_id="E2">
          <title>Maraviroc Unexposed</title>
          <description>HIV-1 infected, treatment-experienced adult participants, who were not prescribed with maraviroc but with OBT regimen (in usual clinical practice following the approved local label of maraviroc), were included in this study and were observed in this study for an observation period of up to 5 years following enrollment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v21.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="435" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="352" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Anaemia of chronic disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Heparin-induced thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Lymphocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Methaemoglobinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Sickle cell anaemia with crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cardiac ventricular thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Torsade de pointes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Fanconi syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Sickle cell disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness bilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Adrenal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Autoimmune hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Central vision loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Orbital cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pupils unequal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Anal skin tags</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Anogenital dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Anorectal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Barretts oesophagus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Crohns disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Haemorrhoids thrombosed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Intestinal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Oesophageal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Oesophageal rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pancreatic pseudocyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Proctitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Rectal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Multi-organ disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Physical deconditioning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Treatment noncompliance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Biliary dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Jarisch-Herxheimer reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>AIDS related complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>AIDS retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Acquired immunodeficiency syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Acute hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Amoebic dysentery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Anorectal cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Aspergillus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Atypical mycobacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Bacterial diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Brain abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Burkholderia cepacia complex sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>CNS ventriculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cerebral toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Corneal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cryptococcal fungaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cryptococcosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cryptosporidiosis infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus chorioretinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>End stage AIDS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>External ear cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Eye infection syphilitic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Fungal oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Gastroenteritis clostridial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Gastroenteritis cryptosporidial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Genital herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Gonorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>HIV enteropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>HIV wasting syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>HIV-associated neurocognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hepatitis B reactivation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Herpes pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Herpes zoster disseminated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Histoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Joint abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Latent syphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Meningitis cryptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Meningitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Microsporidia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Mycobacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Mycobacterium abscessus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Mycobacterium avium complex infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Mycobacterium fortuitum infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Neurosyphilis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Oral hairy leukoplakia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Parvovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pneumonia pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Progressive multifocal leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Salmonella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Secondary syphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Septic embolus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Shigella infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Sinusitis fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Superinfection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Syphilis anal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Trichomoniasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Vascular device infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Breast injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Foreign body in gastrointestinal tract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Foreign body in respiratory tract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Radial nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Splenic injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Traumatic liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Vascular graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Atypical mycobacterium test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Biopsy lymph gland</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Culture stool positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Drug clearance increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Electrocardiogram repolarisation abnormality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>HIV test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Haemophilus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Staphylococcus test</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Staphylococcus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Electrolyte depletion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Folate deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Haemochromatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Diastasis recti abdominis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Anal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Anal cancer stage 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Anal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Anaplastic large cell lymphoma T- and null-cell types</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Burkitts lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Fibrous histiocytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Gastrointestinal lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hodgkins disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Kaposis sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Malignant melanoma stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of unknown primary site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Metastases to pleura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Neoplasm prostate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Non-Hodgkins lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Ocular neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Papillary cystadenoma lymphomatosum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Plasmablastic lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Rectal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Small cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>T-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Vaginal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Vulval cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Infected neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholic seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Amputation stump pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Clonic convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cranial nerve palsies multiple</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Diabetic hyperglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Encephalitis post varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Lacunar stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Parkinsons disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Unresponsive to stimuli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Borderline personality disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Homicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Organic brain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Substance-induced psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Renal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast enlargement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Fallopian tube obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Ovarian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Painful erection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pelvic adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Perineal rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Testicular swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pulmonary eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Lipodystrophy acquired</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Neurodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Abscess drainage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Arterial stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cardiac resynchronisation therapy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Colostomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Gastric banding reversal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hip surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Immune tolerance induction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Leg amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Medical device removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Renal transplant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Valvuloplasty cardiac</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Aortic arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Bleeding varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Subclavian artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Vascular stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Vasospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA v21.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1130"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1316"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

